|
Abstract:
Prostate cancer is the most frequently diagnosed cancer among men in the United States, excluding non-melanoma skin cancer. Few risk factors and prevention strategies for prostate cancer are known. Some evidence suggests that statins, a class of medications that lower cholesterol, may reduce the incidence and progression of prostate cancer. Dr. Farwell obtained training that allowed him to investigate the relationship between statins and prostate cancer incidence and progression. He took classes at the Harvard School of Public Health and had regular research meetings with researchers at the Brigham and Women's Hospital and the VA Boston Healthcare System. He assembled datasets and performed analyses that examined the relationship between statins and total prostate cancer incidence as well as the incidence of both low and high grade prostate cancer.
| Limitations: |
 APPROVED FOR PUBLIC RELEASE |
| Description: |
Annual rept. 1 Sep 2008-31 Aug 2011 |
| Pages: |
40 |
| Report Date: |
Sep 2011 |
| Contract Number: |
W81XWH-08-2-0168 |
| Report Number: |
A594355 |
|
|
|
|
|
Keywords relating to this report:
Email This Abstract
